{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:33:28Z","timestamp":1788813208518,"version":"build-2803163510"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10549-026-08012-5","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T08:42:40Z","timestamp":1783672960000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4\/6 inhibitor for ER-positive\/HER2-negative advanced breast cancer: EVERGREEN study"],"prefix":"10.1007","volume":"218","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7214-4818","authenticated-orcid":false,"given":"Diogo","family":"Martins-Branco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5847-7192","authenticated-orcid":false,"given":"Soraia","family":"Lobo-Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9946-4726","authenticated-orcid":false,"given":"Philippe","family":"Aftimos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2666-6500","authenticated-orcid":false,"given":"Bernardo","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9568-238X","authenticated-orcid":false,"given":"Leonor","family":"Vasconcelos de Matos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6655-0986","authenticated-orcid":false,"given":"Leonor","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3954-5238","authenticated-orcid":false,"given":"Elsa","family":"Camp\u00f4a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7864-3637","authenticated-orcid":false,"given":"Guilherme","family":"Nader-Marta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5141-513X","authenticated-orcid":false,"given":"Donatienne","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5429-7888","authenticated-orcid":false,"given":"Francois P.","family":"Duhoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4734-7621","authenticated-orcid":false,"given":"Pedro","family":"Sim\u00f5es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Rita","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6312-0067","authenticated-orcid":false,"given":"Caterina","family":"Confente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1377-3032","authenticated-orcid":false,"given":"Diogo","family":"Alpuim Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1859-6645","authenticated-orcid":false,"given":"Catarina","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7993-4399","authenticated-orcid":false,"given":"Marianne","family":"Paesmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3038-235X","authenticated-orcid":false,"given":"Frederico","family":"Sarmento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4199-7252","authenticated-orcid":false,"given":"Teresa","family":"Gantes Padr\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7638-9129","authenticated-orcid":false,"given":"Diana","family":"Sim\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6128-1350","authenticated-orcid":false,"given":"Daniel","family":"Bandarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2287-4799","authenticated-orcid":false,"given":"Berta","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6104-5902","authenticated-orcid":false,"given":"Margarida","family":"Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1664-2369","authenticated-orcid":false,"given":"Andrea","family":"Gombos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5153-1766","authenticated-orcid":false,"given":"Lieveke","family":"Ameye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9501-4509","authenticated-orcid":false,"given":"Evandro","family":"de Azambuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"8012_CR1","doi-asserted-by":"crossref","unstructured":"Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N et al (2016) Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. The Lancet Oncol [Internet]. 17(4):425\u2013439. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26947331\/. 2025 Feb 2","DOI":"10.1016\/S1470-2045(15)00613-0"},{"issue":"20","key":"8012_CR2","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Di\u00e9ras V, Slamon DJ (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med [Internet]. 375(20):1925\u20131936. Available from: https:\/\/doi.org\/10.1056\/NEJMoa1607303. 2025 Feb 2","journal-title":"N Engl J Med"},{"issue":"24","key":"8012_CR3","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Mart\u00edn M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Vidam G, Wang Y, Rodriguez Lorenc K, Miller M, Taran T, Jerusalem G (2018) Phase III Randomized study of Ribociclib and fulvestrant in hormone receptor\u2013positive, human Epidermal Growth Factor receptor 2\u2013negative advanced breast cancer: MONALEESA-3. JCO [Internet]. 36(24):2465\u20132472. Available from: https:\/\/doi.org\/10.1200\/JCO.2018.78.9909.","journal-title":"JCO"},{"issue":"7","key":"8012_CR4","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","volume":"29","author":"GN Hortobagyi","year":"2018","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O\u2019Shaughnessy J (2018) Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol [Internet]. 29(7):1541\u20131547. Available from: https:\/\/doi.org\/10.1093\/annonc\/mdy155. 2025 Feb 2","journal-title":"Ann Oncol"},{"issue":"7","key":"8012_CR5","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","volume":"19","author":"D Tripathy","year":"2018","unstructured":"Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im Y-H, Kuemmel S, El-Saghir N, Liu M-C, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu Y-S (2018 Jul 1) Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. The Lancet Oncol [Internet]. 19(7):904\u2013915. Available from: https:\/\/doi.org\/10.1016\/S1470-2045(18)30292-4. 2025 Feb 2","journal-title":"The Lancet Oncol"},{"issue":"25","key":"8012_CR6","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge","year":"2017","unstructured":"Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke E-M, Frenzel M, Lin Y, Barriga S, Smith IC, Bourayou N, Llombart-Cussac A (2017 Sep 1) MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2\u2212 advanced breast cancer who had progressed while receiving endocrine therapy. JCO [Internet]. 35(25):2875\u20132884. Available from: https:\/\/doi.org\/10.1200\/JCO.2017.73.7585. 2025 Feb 2","journal-title":"JCO"},{"issue":"32","key":"8012_CR7","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Tr\u00e9dan O, Chen S-C, Manso L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, Smith IC, Bourayou N, Di Leo A (2017 Nov 10) MONARCH 3: abemaciclib as Initial therapy for advanced breast cancer. JCO [Internet]. 35(32):3638\u20133646. Available from: https:\/\/doi.org\/10.1200\/JCO.2017.75.6155. 2025 Feb 2","journal-title":"JCO"},{"key":"8012_CR8","unstructured":"Palbociclib (IBRANCE) | FDA [Internet]. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/palbociclib-ibrance. 2025 Feb 22]"},{"key":"8012_CR9","unstructured":"Ibrance | European Medicines Agency (EMA) [Internet]. [https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ibrance. 2025 Feb 2]"},{"key":"8012_CR10","unstructured":"Kisqali | European Medicines Agency (EMA) [Internet]. [https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kisqali. 2025 Feb 2]"},{"key":"8012_CR11","unstructured":"Verzenios | European Medicines Agency (EMA) [Internet]. [https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/verzenios. 2025 Feb 2]"},{"key":"8012_CR12","unstructured":"ESMO Metastatic Breast Cancer Living Guidelines, 1.2 April 2025 [Internet]. [cited 2025 May 23]. Available from: https:\/\/www.esmo.org\/guidelines\/living-guidelines\/esmo-living-guideline-metastatic-breast-cancer"},{"issue":"12","key":"8012_CR13","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, Cort\u00e9s J, de Azambuja E, DeMichele A, Dent R, Fenlon D, Gligorov J, Hurvitz SA, Im S-A, Krug D, Kunz WG, Loi S, Penault-Llorca F, Ricke J, Robson M, Rugo HS, Saura C, Schmid P, Singer CF, Spanic T, Tolaney SM, Turner NC, Curigliano G, Loibl S, Paluch-Shimon S, Harbeck N (2021 Dec 1) ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer \u2606. Ann Oncol [Internet]. 32(12):1475\u20131495. Available from: https:\/\/doi.org\/10.1016\/j.annonc.2021.09.019. 2025 Feb 2","journal-title":"Ann Oncol"},{"issue":"19","key":"8012_CR14","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.1158\/1078-0432.CCR-24-1073","volume":"30","author":"A Bardia","year":"2024","unstructured":"Bardia A, Cort\u00e9s J, Bidard FC, Neven P, Garcia-S\u00e1enz J, Aftimos P, O\u2019Shaughnessy J, Lu J, Tonini G, Scartoni S, Paoli A, Binaschi M, Wasserman T, Kaklamani V (2024 Oct 1) Elacestrant in ER+, HER2\u2212 metastatic breast cancer with ESR1 -mutated tumors: subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4\/6 inhibitor and in clinical subgroups. Clin Cancer Res [Internet]. 30(19):4299\u20134309. Available from: https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1073. 2025 Feb 22","journal-title":"Clin Cancer Res"},{"issue":"11","key":"8012_CR15","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.annonc.2025.07.017","volume":"36","author":"D Trapani","year":"2025","unstructured":"Trapani D, Martins-Branco D, Curigliano G, Gennari A, Pentheroudakis G, Harbeck N (2025 Nov 1) Updated treatment recommendations for systemic treatment: from the ESMO metastatic breast cancer living guideline. Ann Oncol [Internet]. 36(11):1414\u20131418. Available from: https:\/\/doi.org\/10.1016\/j.annonc.2025.07.017. 2026 Jun 5","journal-title":"Ann Oncol"},{"key":"8012_CR16","doi-asserted-by":"publisher","unstructured":"de Azambuja E, Barrios CH, Bartsch R, Curigliano G, Dent R, Gennari A, Loi S, Paluch-Shimon S, Pistilli B, Saura C, Schmid P, Spanic T, Toi M, Tolaney SM, Harbeck N (2026 May) Metastatic breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2020. Ann Oncol [Internet]. Available from: https:\/\/doi.org\/10.1016\/j.annonc.2026.05.707. 2026 Jun 5\u00a0","DOI":"10.1016\/j.annonc.2026.05.707"},{"issue":"7","key":"8012_CR17","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","volume":"35","author":"MF Mosele","year":"2024","unstructured":"Mosele MF, Westphalen CB, Stenzinger A, Barlesi F, Bayle A, Bi\u00e8che I, Bonastre J, Castro E, Dienstmann R, Kr\u00e4mer A, Czarnecka AM, Meric-Bernstam F, Michiels S, Miller R, Normanno N, Reis-Filho J, Remon J, Robson M, Rouleau E, Scarpa A, Serrano C, Mateo J, Andr\u00e9 F (2024) Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO precision medicine working group. Ann Oncol [Internet]. 35(7):588\u2013606. Available from: https:\/\/doi.org\/10.1016\/j.annonc.2024.04.005. 2024 Jul 10","journal-title":"Ann Oncol"},{"issue":"11","key":"8012_CR18","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1158\/2159-8290.CD-20-1647","volume":"11","author":"P Aftimos","year":"2021","unstructured":"Aftimos P, Oliveira M, Irrthum A, Fumagalli D, Sotiriou C, Gal-Yam EN, Robson ME, Ndozeng J, Di Leo A, Ciruelos EM, de Azambuja E, Viale G, Scheepers ED, Curigliano G, Bliss JM, Reis-Filho JS, Colleoni M, Balic M, Cardoso F, Albanell J, Duhem C, Marreaud S, Romagnoli D, Rojas B, Gombos A, Wildiers H, Guerrero-Zotano A, Hall P, Bonetti A, Larsson KF, Degiorgis M, Khodaverdi S, Greil R, Sverrisd\u00f3ttir \u00c1, Paoli M, Seyll E, Loibl S, Linderholm B, Zoppoli G, Davidson NE et al. (2021 Nov 1) Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the breast international group (BIG) molecular screening initiative. Cancer DiscovCancer Discov [Internet]. 11(11):2796\u20132811. Available from: https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1647. 2025 Feb 2","journal-title":"Cancer DiscovCancer Discov"},{"issue":"3","key":"8012_CR19","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10549-024-07376-w","volume":"207","author":"MA Bhave","year":"2024","unstructured":"Bhave MA, Quintanilha JCF, Tukachinsky H, Li G, Scott T, Ross JS, Pasquina L, Huang RSP, McArthur H, Levy MA, Graf RP, Kalinsky K (2024 Oct 1) Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(\u2212) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice. Breast Cancer Res Treat [Internet]. 207(3):599. Available from: https:\/\/doi.org\/10.1007\/s10549-024-07376-w. 2025 Feb 2","journal-title":"Breast Cancer Res Treat"},{"issue":"28","key":"8012_CR20","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/JCO.22.00338","volume":"40","author":"FC Bidard","year":"2022","unstructured":"Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, Mouret-Reynier M-A, Sohn JH, Taylor D, Harnden KK, Khong H, Kocsis J, Dalenc F, Dillon PM, Babu S, Waters S, Deleu I, Garc\u00eda S\u00e1enz JA, Bria E, Cazzaniga M, Lu J, Aftimos P, Cort\u00e9s J, Liu S, Tonini G, Laurent D, Habboubi N, Conlan MG, Bardia A (2022 May 1) Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor\u2013positive, human Epidermal Growth Factor receptor 2\u2013negative advanced breast cancer: results from the Randomized phase III EMERALD trial. JCO [Internet]. 40(28). Available from: 3246\u20133256. https:\/\/doi.org\/10.1200\/JCO.22.00338. 2025 Feb 2","journal-title":"JCO"},{"key":"8012_CR21","unstructured":"Piqray | European Medicines Agency (EMA) [Internet]. [https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/piqray. 2025 Feb 2]."},{"issue":"20","key":"8012_CR22","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9 F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu Y-S, Inoue K, Takahashi M, P\u00e1pai Z, Longin A-S, Mills D, Wilke C, Hirawat S, Juric D (2019 May 16) Alpelisib for PIK3CA -Mutated, hormone receptor\u2013positive advanced breast cancer. N Engl J Med [Internet]. 380(20):1929\u20131940. Available from: https:\/\/doi.org\/10.1056\/NEJMoa1813904. 2025 Feb 2","journal-title":"N Engl J Med"},{"issue":"4","key":"8012_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(21)00034-6","volume":"22","author":"HS Rugo","year":"2021","unstructured":"Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, Park YH, Prat A, Bachelot T, Juric D, Turner N, Sophos N, Zarate JP, Arce C, Shen Y-M, Turner S, Kanakamedala H, Hsu W-C, Chia S (2021 Apr 1) Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. The Lancet Oncol [Internet]. 22(4):489\u2013498. Available from: https:\/\/doi.org\/10.1016\/S1470-2045(21)00034-6. 2025 Feb 2","journal-title":"The Lancet Oncol"},{"issue":"22","key":"8012_CR24","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS (2023 Jun 1) Capivasertib in hormone receptor\u2013positive advanced breast cancer. N Engl J Med [Internet]. 388(22):2058\u20132070. Available from: https:\/\/doi.org\/10.1056\/NEJMoa2214131. 2025 Feb 2","journal-title":"N Engl J Med"},{"key":"8012_CR25","unstructured":"Truqap | European Medicines Agency (EMA) [Internet]. [https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/truqap. 2025 Feb 2]."},{"key":"8012_CR26","unstructured":"Orserdu | European Medicines Agency (EMA) [Internet]. [https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/orserdu. 2025 Feb 2]."},{"issue":"15","key":"8012_CR27","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1158\/1078-0432.CCR-21-3811","volume":"28","author":"GJ Lindeman","year":"2022","unstructured":"Lindeman GJ, Fernando TM, Bowen R, Jerzak KJ, Song X, Decker T, Boyle F, McCune S, Armstrong A, Shannon C, Bertelli G, Chang C-W, Desai R, Gupta K, Wilson TR, Flechais A, Bardia A (2022 Aug 1) VERONICA: randomized phase II study of fulvestrant and venetoclax in ER-Positive metastatic breast cancer post-CDK4\/6 inhibitors \u2013 efficacy, safety, and biomarker results. Clin Cancer Res [Internet]. 28(15):3256\u20133267. Available from: https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3811. 2025 Feb 2","journal-title":"Clin Cancer Res"},{"issue":"24","key":"8012_CR28","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1200\/JCO.22.02392","volume":"41","author":"K Kalinsky","year":"2023","unstructured":"Kalinsky K, Accordino MK, Chiuzan C, Mundi PS, Sakach E, Sathe C, Ahn H, Trivedi MS, Novik Y, Tiersten A, Raptis G, Baer LN, Oh SY, Zelnak AB, Wisinski KB, Andreopoulou E, Gradishar WJ, Stringer-Reasor E, Reid SA, O\u2019Dea A, O\u2019Regan R, Crew KD, Hershman DL (2023 Aug 20) Randomized phase II trial of endocrine therapy with or without ribociclib after progression on Cyclin-dependent kinase 4\/6 Inhibition in hormone receptor\u2013positive, human Epidermal Growth Factor receptor 2\u2013negative metastatic breast cancer: MAINTAIN trial. JCO [Internet]. 41(24):4004\u20134013. Available from: https:\/\/doi.org\/10.1200\/JCO.22.02392. 2025 Feb 2","journal-title":"JCO"},{"issue":"17","key":"8012_CR29","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1200\/JCO.23.01940","volume":"42","author":"EL Mayer","year":"2024","unstructured":"Mayer EL, Ren Y, Wagle N, Mahtani R, Ma C, Demichele A et al. (2024 Jun 10) PACE: a Randomized phase II study of fulvestrant, palbociclib, and avelumab after progression on Cyclin-dependent kinase 4\/6 inhibitor and aromatase inhibitor for hormone receptor-Positive\/Human Epidermal Growth Factor receptor-negative metastatic breast cancer. J Clin Oncol [Internet]. 42(17):2050\u20132060. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38513188\/. 2025 Feb 2","journal-title":"J Clin Oncol"},{"key":"8012_CR30","unstructured":"Kalinsky K, Bianchini G, Hamilton E, Graff SL, Park KH, Jeselsohn R et al. (2024 Dec 18 [cited 2025 Feb 2];JCO2402086. Available from: Abemaciclib plus fulvestrant in advanced breast cancer after progression on CDK4\/6 Inhibition: results from the phase III postMONARCH trial. J Clin Oncol [Internet]. https:\/\/pubmed.ncbi.nlm.nih.gov\/39693591\/"},{"key":"8012_CR31","unstructured":"Afinitor | European Medicines Agency (EMA) [Internet]. [https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/afinitor. 2025 Feb 2]."},{"issue":"6","key":"8012_CR32","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M, Burris HAI, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN (2012 Feb 9) Everolimus in postmenopausal hormone-Receptor\u2013Positive advanced breast cancer. N Engl J Med [Internet]. 366(6):520\u2013529. Available from: https:\/\/doi.org\/10.1056\/NEJMoa1109653. 2025 Feb 2","journal-title":"N Engl J Med"},{"key":"8012_CR33","doi-asserted-by":"publisher","unstructured":"O\u2019Brien NA, McDermott MSJ, Conklin D, Luo T, Ayala R, Salgar S, Chau K, DiTomaso E, Babbar N, Su F, Gaither A, Hurvitz SA, Linnartz R, Rose K, Hirawat S, Slamon DJ (2020 Aug 14) Targeting activated PI3K\/mTOR signaling overcomes acquired resistance to CDK4\/6-based therapies in preclinical models of hormone receptor-positive breast cancer. Breast Cancer Res [Internet]. 22(1). Available from: https:\/\/doi.org\/10.1186\/s13058-020-01320-8. 2025 Feb 2","DOI":"10.1186\/s13058-020-01320-8"},{"issue":"5","key":"8012_CR34","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s12282-020-01090-3","volume":"27","author":"M Iida","year":"2020","unstructured":"Iida M, Toyosawa D, Nakamura M, Tsuboi K, Tokuda E, Niwa T, Ishida T, Hayashi S-I (2020 Sep 1) Decreased ER dependency after acquired resistance to CDK4\/6 inhibitors. Breast Cancer [Internet]. 27(5):963\u2013972. Available from: https:\/\/doi.org\/10.1007\/s12282-020-01090-3. 2025 Feb 2","journal-title":"Breast Cancer"},{"key":"8012_CR35","doi-asserted-by":"publisher","unstructured":"Rozenblit M, Mun S, Soulos P, Adelson K, Pusztai L, Mougalian S (2021 Dec 1) Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy. Breast Cancer Res [Internet]. 23(1). Available from: https:\/\/doi.org\/10.1186\/s13058-021-01394-y. 2025 Feb 2","DOI":"10.1186\/s13058-021-01394-y"},{"issue":"2","key":"8012_CR36","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/onco.13609","volume":"26","author":"MM Cook","year":"2021","unstructured":"Cook MM, Al Rabadi L, Kaempf AJ, Saraceni MM, Savin MA, Mitri ZI (2021 Feb 1) Everolimus plus exemestane treatment in patients with metastatic hormone receptor-positive breast cancer Previously treated with CDK4\/6 inhibitor therapy. Oncologist [Internet]. 26(2):101\u2013106. Available from: https:\/\/doi.org\/10.1002\/onco.13609. 2025 Feb 2","journal-title":"Oncologist"},{"issue":"2","key":"8012_CR37","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.clbc.2021.10.002","volume":"22","author":"H Mo","year":"2022","unstructured":"Mo H, Renna CE, Moore HCF, Abraham J, Kruse ML, Montero AJ, LeGrand SB, Wang L, Budd GT (2022 Feb 1) Real-world outcomes of everolimus and exemestane for the treatment of metastatic hormone receptor-positive breast cancer in patients Previously treated with CDK4\/6 inhibitors. Clin Breast Cancer [Internet]. 22(2):143\u2013148. Available from: https:\/\/doi.org\/10.1016\/j.clbc.2021.10.002. 2025 Feb 2","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"8012_CR38","doi-asserted-by":"publisher","first-page":"141","DOI":"10.6004\/jnccn.2018.7094","volume":"17","author":"J Xi","year":"2019","unstructured":"Xi J, Oza A, Thomas S, Ademuyiwa F, Weilbaecher K, Suresh R, Bose R, Cherian M, Hernandez-Aya L, Frith A, Peterson L, Luo J, Krishnamurthy J, Ma CX (2019 Feb) Retrospective analysis of treatment patterns and effectiveness of palbociclib and subsequent regimens in metastatic breast cancer. J Natl Compr Cancer Network 17(2):141\u2013147. https:\/\/doi.org\/10.6004\/jnccn.2018.7094","journal-title":"J Natl Compr Cancer Network"},{"key":"8012_CR39","doi-asserted-by":"crossref","unstructured":"Dhakal A, Antony Thomas R, Levine EG, Brufsky A, Takabe K, Hanna MG et al. (2020;. 14 [cited 2025 Feb 2] Available from: Outcome of everolimus-based therapy in hormone-receptor-positive metastatic breast cancer patients after progression on palbociclib. Breast cancer (auckl) [Internet]. https:\/\/pubmed.ncbi.nlm.nih.gov\/32753876\/","DOI":"10.1177\/1178223420944864"},{"issue":"16","key":"8012_CR40","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41388-024-02986-6","volume":"43","author":"A Vasseur","year":"2024","unstructured":"Vasseur A, Cabel L, Hego C, Takka W, Trabelsi Grati O, Renouf B, Lerebours F, Loirat D, Brain E, Cottu P, Sablin M-P, Pierga J-Y, Callens C, Renault S, Bidard F-C (2024 Apr 12) Fulvestrant and everolimus efficacy after CDK4\/6 inhibitor: a prospective study with circulating tumor DNA analysis. Oncogene [Internet]. 43(16):1214\u20131222. Available from: https:\/\/doi.org\/10.1038\/s41388-024-02986-6. 2025 Feb 2","journal-title":"Oncogene"},{"issue":"3","key":"8012_CR41","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s10549-024-07324-8","volume":"206","author":"R S\u00e1nchez-Bayona","year":"2024","unstructured":"S\u00e1nchez-Bayona R, Lopez de Sa A, Jerez Gilarranz Y, Sanchez de Torre A, Alva M, Echavarria I, Moreno F, Tolosa P, Herrero Lopez B, de Luna A, Lema L, Gamez Casado S, Madariaga A, L\u00f3pez-Tarruella S, Manso L, Bueno-Mui\u00f1o C, Garcia-Saenz JA, Ciruelos E, Martin M (2024 Aug 1) Everolimus plus endocrine therapy beyond CDK4\/6 inhibitors progression for HR+ \/HER2\u2212 advanced breast cancer: a real-world evidence cohort. Breast Cancer Res Treat [Internet]. 206(3):551\u2013559. Available from: https:\/\/doi.org\/10.1007\/s10549-024-07324-8. 2025 Feb 2","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"8012_CR42","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/j.1524-4733.2009.00600.x","volume":"12","author":"ML Berger","year":"2009","unstructured":"Berger ML, Mamdani M, Atkins D, Johnson ML (2009) Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good research practices for retrospective Database analysis Task Force report-Part I. Value Health [Internet]. 12(8):1044\u20131052. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19793072\/. 2025 Feb 2","journal-title":"Value Health"},{"issue":"8","key":"8012_CR43","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/j.1524-4733.2009.00601.x","volume":"12","author":"E Cox","year":"2009","unstructured":"Cox E, Martin BC, Van Staa T, Garbe E, Siebert U, Johnson ML (2009 Nov 1) Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the international Society for Pharmacoeconomics and outcomes research Good research practices for retrospective Database analysis Task Force report-Part II. Value Heal 12(8):1053\u20131061","journal-title":"Value Heal"},{"issue":"8","key":"8012_CR44","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1111\/j.1524-4733.2009.00602.x","volume":"12","author":"ML Johnson","year":"2009","unstructured":"Johnson ML, Crown W, Martin BC, Dormuth CR, Siebert U (2009) Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good research practices for retrospective Database analysis Task Force report-Part III. Value Health [Internet]. 12(8):1062\u20131073. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19793071\/. 2025 Feb 2","journal-title":"Value Health"},{"issue":"12","key":"8012_CR45","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.annonc.2023.10.001","volume":"34","author":"L Castelo-Branco","year":"2023","unstructured":"Castelo-Branco L, Pellat A, Martins-Branco D, Valachis A, Derksen JWG, Suijkerbuijk KPM, Dafni U, Dellaporta T, Vogel A, Prelaj A, Groenwold RHH, Martins H, Stahel R, Bliss J, Kather J, Ribelles N, Perrone F, Hall PS, Dienstmann R, Booth CM, Pentheroudakis G, Delaloge S, Koopman M (2023 Dec 1) ESMO Guidance for reporting Oncology real-world evidence (GROW). Ann Oncol [Internet]. 34(12):1097\u20131112. Available from: https:\/\/doi.org\/10.1016\/j.annonc.2023.10.001. 2025 Feb 2","journal-title":"Ann Oncol"},{"issue":"5","key":"8012_CR46","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis [Internet]. 40(5):373\u2013383. Available from: https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8. 2025 Feb 2","journal-title":"J Chronic Dis"},{"issue":"8","key":"8012_CR47","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","volume":"34","author":"P Tarantino","year":"2023","unstructured":"Tarantino P, Viale G, Press MF, Hu X, Penault-Llorca F, Bardia A, Batistatou A, Burstein HJ, Carey LA, Cortes J, Denkert C, Di\u00e9ras V, Jacot W, Koutras AK, Lebeau A, Loibl S, Modi S, Mosele MF, Provenzano E, Pruneri G, Reis-Filho JS, Rojo F, Salgado R, Schmid P, Schnitt SJ, Tolaney SM, Trapani D, Vincent-Salomon A, Wolff AC, Pentheroudakis G, Andr\u00e9 F, Curigliano G (2023 Aug 1) ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann Oncol [Internet]. 34(8):645\u2013659. Available from: https:\/\/doi.org\/10.1016\/j.annonc.2023.05.008. 2025 Feb 2","journal-title":"Ann Oncol"},{"issue":"1","key":"8012_CR48","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/cpt.2453","volume":"111","author":"DR Rivera","year":"2022","unstructured":"Rivera DR, Henk HJ, Garrett-Mayer E, Christian JB, Belli AJ, Bruinooge SS, Espirito JL, Sweetnam C, Izano MA, Natanzon Y, Robert NJ, Walker MS, Cohen AB, Boyd M, Enewold L, Hansen E, Honnold R, Kushi L, Mishra Kalyani PS, Pe Benito R, Sakoda LC, Sharon E, Tymejczyk O, Valice E, Wagner J, Lasiter L, Allen JD (2022 Jan 1) The friends of cancer research real-world data collaboration pilot 2.0: methodological Recommendations from Oncology case studies. Clin Pharma Ther [Internet]. 111(1):283. Available from: https:\/\/doi.org\/10.1002\/cpt.2453. 2026 Jun 5","journal-title":"Clin Pharma Ther"},{"key":"8012_CR49","doi-asserted-by":"publisher","first-page":"100649","DOI":"10.1016\/j.esmorw.2025.100649","volume":"10","author":"PAJ Vissers","year":"2025","unstructured":"Vissers PAJ, Elferink MAG, Bijlsma MJ, van der Geest LG, Koopman M, van Laarhoven HWM, Nieuwenhuijzen GAP, van Rossum PSN, Sijtsma FPC, Vink GR, de Vos-Geelen J, Wilmink HW, de Wilt JHW, Verhoeven RHA, van Erning FN (2025 Dec 1) Recommendations and definitions for time-to-event endpoints using real-world data in oncology. ESMO Real World Data Digit Oncol [Internet]. 10:100649. Available from: https:\/\/doi.org\/10.1016\/j.esmorw.2025.100649:. 2026 Jun 5","journal-title":"ESMO Real World Data Digit Oncol"},{"issue":"6","key":"8012_CR50","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.clbc.2022.05.002","volume":"22","author":"D Patt","year":"2022","unstructured":"Patt D, Liu X, Li B, McRoy L, Layman RM, Brufsky A (2022 Aug 1) Real-world treatment patterns and outcomes of palbociclib plus an aromatase inhibitor for metastatic breast cancer: flatiron Database analysis. Clin Breast Cancer [Internet]. 22(6):601\u2013610. Available from: https:\/\/doi.org\/10.1016\/j.clbc.2022.05.002. 2025 Mar 23","journal-title":"Clin Breast Cancer"},{"key":"8012_CR51","unstructured":"U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (2017) Common Terminology Criteria for adverse events (CTCAE) version 5.0. Internet. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf. 2022 May 9]."},{"key":"8012_CR52","unstructured":"ESMO-MCBS scorecards - everolimus [Internet]. https:\/\/www.esmo.org\/guidelines\/esmo-mcbs\/esmo-mcbs-for-solid-tumours\/esmo-mcbs-scorecards\/scorecard-12-1. 2025 Feb 2]."},{"issue":"10","key":"8012_CR53","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","volume":"30","author":"DA Yardley","year":"2013","unstructured":"Yardley DA, Noguchi S, Pritchard KI, Burris HA, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS (2013 Oct 25) Everolimus plus exemestane in postmenopausal patients with HR+ breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther [Internet]. 30(10):870\u2013884. Available from: https:\/\/doi.org\/10.1007\/s12325-013-0060-1. 2025 Feb 2","journal-title":"Adv Ther"},{"issue":"10","key":"8012_CR54","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1001\/jamaoncol.2018.2262","volume":"4","author":"G Jerusalem","year":"2018","unstructured":"Jerusalem G, De Boer RH, Hurvitz S, Yardley DA, Kovalenko E, Ejlertsen B, Blau S, \u00d6zg\u00fcroglu M, Landherr L, Ewertz M, Taran T, Fan J, Noel-Baron F, Louveau A-L, Burris H (2018 Oct 1) Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor\u2013positive, HER2-negative advanced breast cancer. JAMA Oncol [Internet]. 4(10):1367\u20131374. Available from: https:\/\/doi.org\/10.1001\/jamaoncol.2018.2262. 2025 Feb 2","journal-title":"JAMA Oncol"},{"key":"8012_CR55","doi-asserted-by":"crossref","unstructured":"Jacobs F, Molinelli C, Martins-Branco D, Marta GN, Salmon M, Ameye L et al. (2024 Jan 1;. 197 [cited 2024 Jul 10] Available from: Progression-free survival assessment by local investigators versus blinded independent central review in randomized clinical trials in metastatic breast cancer: a systematic review and meta-analysis. Eur J cancer [Internet]. https:\/\/pubmed.ncbi.nlm.nih.gov\/38103328\/","DOI":"10.1016\/j.ejca.2023.113478"},{"issue":"6","key":"8012_CR56","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/oncolo\/oyac075","volume":"27","author":"JM Martin","year":"2022","unstructured":"Martin JM, Handorf EA, Montero AJ, Goldstein LJ (2022 Jun 1) Systemic therapies following progression on first-line CDK4\/6-inhibitor treatment: analysis of real-world data. Oncologist [Internet]. 27(6):441\u2013446. Available from: https:\/\/doi.org\/10.1093\/oncolo\/oyac075. 2025 Feb 2","journal-title":"Oncologist"},{"key":"8012_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.breast.2023.05.006","volume":"70","author":"M Sawaki","year":"2023","unstructured":"Sawaki M, Muramatsu Y, Togo K, Iwata H (2023 Aug 1) Real-world treatment patterns of subsequent therapy after palbociclib in patients with advanced breast cancer in Japan. Breast [Internet]. 70:1\u20137. Available from: https:\/\/doi.org\/10.1016\/j.breast.2023.05.006. 2025 Feb 2","journal-title":"Breast"},{"key":"8012_CR58","unstructured":"Afinitor | European Medicines Agency (EMA) [Internet]. [https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/afinitor. 2026 Jun 5]."},{"issue":"16","key":"8012_CR59","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1200\/JCO.2017.76.9331","volume":"36","author":"N Kornblum","year":"2018","unstructured":"Kornblum N, Zhao F, Manola J, Klein P, Ramaswamy B, Brufsky A et al. (2018 Jun 1) Randomized phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human Epidermal Growth Factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy: results of PrE0102. J Clin Oncol [Internet]. 36(16):1556\u20131563. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29664714\/. 2025 Mar 23","journal-title":"J Clin Oncol"},{"key":"8012_CR60","doi-asserted-by":"crossref","unstructured":"Cherny NI, Trapani D, Galotti M, Saar M, Bricalli G, Roitberg F et al. (2025 Jan) ESMO global consortium study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update. Ann Oncol [Internet]. Available from: http:\/\/www.annalsofoncology.org\/article\/S0923753424049809\/fulltext. 2025 Feb 2","DOI":"10.1016\/j.annonc.2024.12.005"},{"key":"8012_CR61","doi-asserted-by":"publisher","unstructured":"Vernieri C, Corti F, Nichetti F, Ligorio F, Manglaviti S, Zattarin E, Rea CG, Capri G, Bianchi GV, de Braud F (2020 Apr 6) Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K\/AKT\/mTORC1 pathway with different clinical implications. Breast Cancer Res [Internet]. 22(1). Available from: https:\/\/doi.org\/10.1186\/s13058-020-01271-0. 2025 Feb 2","DOI":"10.1186\/s13058-020-01271-0"},{"key":"8012_CR62","unstructured":"FDA approves inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer | FDA [Internet]. [https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-inavolisib-palbociclib-and-fulvestrant-endocrine-resistant-pik3ca-mutated-hr-positive. 2025 Feb 2]."},{"key":"8012_CR63","unstructured":"Jhaveri KL, Neven P, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P et al. (2024 Dec 11) Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med [Internet]. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/39660834. 2025 Feb 2]"},{"issue":"10","key":"8012_CR64","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.annonc.2023.06.011","volume":"34","author":"A Bayle","year":"2023","unstructured":"Bayle A, Bonastre J, Chaltiel D, Latino N, Rouleau E, Peters S, Galotti M, Bricalli G, Besse B, Giuliani R (2023 Oct 1) ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe. Ann Oncol 34(10):934\u2013945. https:\/\/doi.org\/10.1016\/j.annonc.2023.06.011","journal-title":"Ann Oncol"},{"issue":"2","key":"8012_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00245","volume":"2","author":"F Meric-Bernstam","year":"2018","unstructured":"Meric-Bernstam F, Zheng X, Shariati M, Damodaran S, Wathoo C, Brusco L, Demirhan ME, Tapia C, Eterovic AK, Basho RK, Ueno NT, Janku F, Sahin A, Rodon J, Broaddus R, Kim T-B, Mendelsohn J, Mills Shaw KR, Tripathy D, Mills GB, Chen K (2018 Nov) Survival outcomes by TP53 mutation status in metastatic breast cancer. JCO Precis Oncol [Internet]. 2(2):1\u201315. Available from: https:\/\/doi.org\/10.1200\/PO.17.00245. 2025 Feb 2","journal-title":"JCO Precis Oncol"},{"key":"8012_CR66","doi-asserted-by":"crossref","unstructured":"Mayer E, Tolaney S, Martin M, Vidal G, Moscetti L, Jhaveri K et al. (2025 Sep 1) LBA16 giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2- aBC) previously treated with a CDK4\/6 inhibitor (i): prima \u2026. Ann Oncol [Internet]. 36:S1561\u20132. Available from: https:\/\/www.annalsofoncology.org\/action\/showFullText?pii=S0923753425047969. 2026 Jun 5","DOI":"10.1016\/j.annonc.2025.09.026"},{"key":"8012_CR67","doi-asserted-by":"crossref","unstructured":"Llombart-Cussac A, P\u00e9rez-Garc\u00eda JM, Lopez-Miranda E, Saavedra C, Cara\u00f1ana V, Blancas I et al. (2026 Feb 15 [cited 2026 Jun 5];Abstract PS1-11-02. The ADELA study: a double-blind, placebo-controlled, randomized phase 3 trial of elacestrant + everolimus versus elacestrant + placebo in ER+\/HER2- advanced breast cancer (ABC) patients with ESR1-mutated tumors progressing on endocrin \u2026. Clin Cancer Res [Internet]. 32(4_Supplement):PS1\u201311\u201302. Available from: https:\/\/www.clincancerres\/article\/32\/4_Supplement\/PS1-11-02\/772875\/Abstract-PS1-11-02-The-ADELA-study-a-double-blind","DOI":"10.1158\/1557-3265.SABCS25-PS1-11-02"},{"key":"8012_CR68","doi-asserted-by":"publisher","unstructured":"Rugo H, Tolaney SM, Chan N, Borges G, Yerushalmi R, Sharifi M, McHayleh W, Beck T, Vidula N, Hamilton E, Rinn KJ, O\u2019Shaughnessy J, Curigliano G, Cort\u00e9s J, Romero P, Tonini G, Paoli A, Binaschi M, Cheng L, Crozier J, Wasserman T, Kaklamani V (2026 Feb 15) Abstract RF7-01: elacestrant in combination with everolimus or abemaciclib in patients with ER+\/HER2- locally advanced or metastatic breast cancer (mBC): phase 2 results from ELEVATE, an open-label, umbrella study. Clin Cancer Res [Internet]. 32(4_Supplement):RF7\u201301. [cited 2026 Jun 5] Available from: https:\/\/doi.org\/10.1158\/1557-3265.SABCS25-RF7-01","DOI":"10.1158\/1557-3265.SABCS25-RF7-01"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08012-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-08012-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08012-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:02:50Z","timestamp":1785445370000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-08012-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["8012"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-08012-5","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"28 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol (Supplement\n                      \n                      ) was centrally approved by the ethics committee of the study sponsor - Institut Jules Bordet (CE3499) - and by local independent review boards, with exemption of informed consent due to the retrospective and non-interventional nature of the study. Patients with medical records denoting opt-out of personal data use for research purposes were not considered. The study was performed in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate and for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DMB: reports employment from the European Society for Medical Oncology since September 1, 2023; participation as medical research fellow in research studies institutionally funded by Eli Lilly, F. Hoffmann-La Roche Ltd, and Novartis to Institut Jules Bordet (2021\u20132023); and non-financial interests as past member of the Board of Directors for the Associa\u00e7\u00e3o de Investiga\u00e7\u00e3o e Cuidados de Suporte em Oncologia (2022\u20132024) and member of American Society of Clinical Oncology, Associa\u00e7\u00e3o Portuguesa de Cuidados Paliativos, Multinational Association of Supportive Care in Cancer, and Sociedade Portuguesa de Oncologia. SLM: reports honoraria and\/or advisory board from AstraZeneca, BMS, Gilead Sciences MSD, Novartis, Pfizer, and Roche; travel support for attending medical conferences from Amgen, AstraZeneca, BMS, DaiichiSankyo, Gilead Sciences, Lilly, MSD, Novartis, Pfizer, Pierre Fabre, Roche, and Sanofi; participation as medical research fellow in research studies institutionally funded by AstraZeneca, F. Hoffmann-La Roche Ltd, and Novartis to Institut Jules Bordet. PA: reports consultancy fees from Amcure, Boehringer Ingelheim, Daiichi Sankyo, Deloitte, G1 Therapeutics, Macrogenics, Novartis, Radius, Roche, and Servier; honoraria from Amgen, Gilead, Lilly, Menarini, Novartis, and Synthon; travel support for attending medical conferences from Amgen, Daiichi Sankyo, MSD, Pfizer, and Roche; research funding to institution from Roche. LVdM: reports speaker\/consultancy fees from AstraZeneca, Daiichi Sankyo, Lilly, Novartis, Pfizer, and Roche; travel support for attending medical conferences from Lilly, Novartis, Pfizer, and Roche. LF: reports honoraria and\/or advisory board from Gilead, MSD, Novartis and Pfizer; travel support for attending medical conferences\/preceptorships from AstraZeneca\/Daiichi Sankyo, Gilead, MSD, Novartis, Pierre Fabre, Pfizer and Servier. GNM: reports travel support for attending medical conferences from AstraZeneca. DT: reports advisory board honoraria from AstraZeneca, Daiichii Sankyo, Eli Lilly, Exact Sciences, Menarini-Stemline, and Novartis; travel support for attending medical conferences from Gilead; speaker fees from Menarini-Stemline. FPD: reports consultancy and advisory role fees to institution from Amgen, AstraZeneca, DaiichiSankyo, Gilead Sciences, Lilly, Menarini, MSD Oncology, Novartis, Pierre Fabre, Pfizer, Roche, and Seattle Genetics; travel support for attending medical conferences from Amgen, DaiichiSankyo\/AstraZeneca, Gilead Sciences, Pfizer, Roche, and Teva. DAC: reports research grants from AstraZeneca Produtos Farmac\u00eauticos LDA, Grupo Jos\u00e9 de Mello, and Laborat\u00f3rio Germano de Sousa; consultancy fees from NTT Data; speaker fees, publication writing or educational events from Ahed, AIM Cancer Center, AstraZeneca, FAES FARMA, Hoffmann-La Roche, Merck KGaA, Merck Sharp & Dohme, Nestl\u00e9, Novartis, Nutricia, Pfizer, and Uriage; travel support for attending medical conferences from AstraZeneca, Daiichi Sankyo, GlaxoSmithKline, Hoffmann-La Roche, Merck KGaA, Merck Sharp & Dohme, Novartis, Nutricia, and Pfizer; honoraria from participation on data safety monitoring board or advisory board from Hoffmann-La Roche, Nestl\u00e9, Novartis, and Pfizer; leadership or fiduciary role in other board, society, committee or advocacy group at ESMO Faculty Group for Head and Neck Cancer, and Grupo de Estudos de Cancro de Cabe\u00e7a e Pesco\u00e7o; receipt of equipment, materials, drugs, medical writing, gifts or other services from Pfizer, and Uriage. BS: reports expert testimony fees from Merck Sharp & Dohme, Novartis, and Roche; expert testimony fees to her institution from Novartis; travel support for attending medical conferences from Amgen, Astra Zeneca, Daichii Sankyo, Glaxo SmithKline, Merck Sharp & Dohme, Novartis, Pfizer, Pierre-Fabre, and Roche. AG: reports honoraria to her institution from Daiichi Sankyo, MSD Oncology, Novartis, and Roche; consulting or advisory role fees to her institution from AstraZeneca Belgium and Daiichi Sankyo Belgium; travel support to her institution for attending medical conferences from Daiichi Sankyo Belgium, Gilead Sciences, and Lilly. EdA: reports honoraria and\/or advisory board fees from AstraZeneca, Gilead Sciences, Libbs, Lilly, MSD, Novartis, Pierre Fabre, Roche\/GNE, SeaGen, Zodiac; travel support for attending medical conferences from Astra-Zeneca and Gilead; research grant to his institution from Astra-Zeneca, Gilead Sciences, GSK\/Novartis, Roche\/GNE, and Seagen\/Pfizer; non-financial interest due to leadership role as BSMO President 2023\u20132026 and ESMO Director of Membership 2023\u20132025. No competing interests to declare: BP, EC, MM, PS, ARG, VP, CC, JP, CS, MP, FS, TGP, DS, DB, MB, and LA.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"7"}}